ToposBio

Redefining druggable space with AI-driven protein modeling.

[Gladstone Institutes @GladstoneInst]

At Gladstone, collaboration fuels discovery. Our partnership with @ToposBio brings together AI-powered protein modeling and deep expertise in neurodegenerative disease to explore new therapeutic options for conditions like Parkinson’s and Alzheimer’s.

https://t.co/rwxSXlzY9B

[ToposBio @ToposBio]

Powered by @Modal compute; shout out to @charles_irl
Excited to contribute to #DrugDesign #AI #Biology

[ToposBio @ToposBio]

Announcing Topos-1, an all-atom generative model that sets a new benchmark for predicting structural ensembles of intrinsically disordered proteins. Topos-1 outperforms existing models by a large margin, with implications for designing drugs for challenging targets ranging from cancer to neurodegenerative disease.

Read the full technical report on our website: https://t.co/3UtTSdmddf

[ToposBio @ToposBio]

Topos-1 is only the beginning: we’re rapidly expanding its capabilities and the favorable scaling results so far indicate a steep improvement curve. To learn more about the model and its evals, check out our technical report: https://t.co/M0cTFbJi22

[ToposBio @ToposBio]

Using Topos-1, we generated conformational ensembles that provided drug design insight and lead to computational predictions of drug potency that are in good agreement with tests performed in our laboratory.